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Abstract
Background: The focus on translational research in clinical trials has the potential to generate clinically relevant
genetic data that could have importance to patients. This raises challenging questions about communicating
relevant genetic research results to individual patients.
Methods: An exploratory pharmacogenetic analysis was conducted in the international ovarian cancer phase III
trial, AGO-OVAR 16, which found that patients with clinically important germ-line BRCA1/2 mutations had improved
progression-free survival prognosis. Mechanisms to communicate BRCA results were evaluated, because these
findings may be beneficial to patients and their families.
Results: Communicating individual BRCA results was not anticipated during clinical trial design. Consequently,
options were not available for patients to indicate their preference for receiving their individual results when they
signed pharmacogenetic informed consent. Differences in local requirements, clinical practice, and opinion
regarding the ethical aspects of how to convey genetic results to patients are all potential barriers to returning
individual BRCA results to patients. Communicating the aggregate BRCA result from this study provided clinical
investigators with a mechanism to disseminate the overall study finding to patients while taking individual
circumstances, local guidelines and clinical practice into account.
Conclusion: This study illustrates the importance of increasing the clarity and scope of informed consent and the
need for patient engagement to ensure clinical trial participants can indicate their preference regarding receipt of
potentially important individual pharmacogenetic results.
Trial registration: This study was registered in the NCT Clinical Trial Registry under NCT00866697 on March 19,
2009, following approval from participating ethics committees (Additional file 1).
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Background
There are numerous arguments in favor of individual
genetic research results being communicated to study
participants, including the right of the participants to re-
ceive potentially important research information about
themselves and the possible benefit from clinically action-
able findings to both participants and their families [1]. In-
deed, research has shown that most research participants
are interested in receiving their genomic research results
[2] and that this interest extends to participants in differ-
ent countries [3]. Arguments against communicating indi-
vidual results include the fact that the significance of the
genetic research results may be uncertain and that there
may be a potential for participants to misinterpret their
results or make ill-informed treatment decisions [4], un-
less they receive genetic counselling and their results are
confirmed in clinically accredited laboratories. Many
countries have ethics guidelines recognizing that explora-
tory genetic results may have limited clinical utility; while
in some other countries regulation provides participants
with the right to access their individual results [5]. In the
United States, where there is no explicit legal requirement
to return genetic research findings [6], the American Col-
lege of Medical Genetics and Genomics suggested that
pathogenic mutations in 56 specified genes should be
returned to patients undergoing clinical exome and gen-
ome sequencing [7], a position that has further added to
the debate on whether similar recommendations are re-
quired in the genetic research setting.
Clinical diagnostic genetic testing utilizes validated
tests that are conducted in accredited laboratories, to as-
sess genetic factors to diagnose or predict disease and/or
to inform treatment options. Pharmacogenetic (PGx) re-
search aims to understand genetic influences on the re-
sponse to medicines. Most PGx analyses are exploratory,
often conducted retrospectively in a non-accredited en-
vironment, and are not designed to inform the clinical
care of the individual study participants. These explora-
tory PGx sub-studies are generally not designed with
communication of individual results in mind, and inter-
national or multicenter clinical studies raise further op-
erational challenges (for example, consent documents
may differ between countries to comply with local law
or practice, and PGx researchers are not in direct con-
tact with study patients). Despite this, the increasingly
routine application of genome-wide approaches in PGx
research increases the probability that researchers may
identify findings with a potential clinical significance to
study participants and their families, raising the question
of how to manage and communicate such findings.
While international policies suggest that there may be
an ethical duty of care to communicate individual gen-
etic research results if certain conditions are met [8],
there is a lack of agreement in guidance between
countries [9], and the potential benefits or harm of shar-
ing non-accredited research results requires further
evaluation [10]. Suggested minimum requirements for
the communication of individual genetic research results
require that results be validated and clinically relevant
[11], where intervention has the potential to influence
treatment or patient management [12]. Furthermore, the
European Commission has highlighted the importance
of the informed consent process and the need for full
transparency on the provision of test results to individ-
uals and populations [13]. However, the informed con-
sent forms for most clinical trials conducted to date
typically do not provide participants with the option to
indicate whether or not they wish to receive their indi-
vidual genetic results.
The AGO-OVAR 16 clinical trial evaluated the efficacy
and safety of pazopanib versus placebo as maintenance
therapy in women with FIGO Stage II-IV epithelial ovar-
ian, fallopian tube, or primary peritoneal cancer who
had not progressed after first-line chemotherapy [14]. It
is well known that germ-line and somatic pathogenic
mutations in the tumor suppressor genes, BRCA1 and
BRCA2 (BRCA1/2), confer increased risk for ovarian
and breast cancers [15]. Other studies, reported after
AGO-OVAR 16 was designed, have shown that these
same mutations confer increased sensitivity to platinum-
based therapies and to poly ADP ribose polymerase
(PARP) inhibitors [16–18]. Given this association and
following a specific question from a regulatory agency,
Harter and colleagues conducted a post-hoc exploratory
analysis to evaluate the potential effect of BRCA1/2 mu-
tation on pazopanib efficacy in AGO-OVAR 16. This
analysis demonstrated that 15 % of participants who
could be evaluated in a PGx sub-study carried a clinic-
ally important germ-line mutation in BRCA1 or BRCA2
(hereafter referred to as a BRCA mutation), which was
associated with better progression-free survival (PFS)
prognosis [19]. Because germ-line pathogenic mutations
in BRCA1/2 are a strong genetic risk factor for breast
and epithelial ovarian cancer [15], and are associated
with disease prognosis and response to treatment [16–18],
the individual research results may be regarded as med-
ically important information for patients who do not
yet have a diagnostic quality BRCA1/2 test result. Al-
though published opinion on the return of results is
helpful, there are limited examples involving the actual
return of PGx research results, and to our knowledge,
of those that have been reported [20], none discuss this
situation in an international clinical trial setting. Here,
we discuss the considerations that led the AGO-OVAR
16 Steering Committee and pharmaceutical sponsor to
develop a framework for communication of BRCA re-
search results to ovarian cancer patients enrolled in
AGO-OVAR 16.
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Methods
Clinical protocol and informed consent
The AGO-OVAR 16 clinical trial (ClinicalTrials.gov
Identifier: NCT00866697) has been previously described
[14]. The clinical protocol and patient informed consent
form (ICF) incorporated a description and objectives of
exploratory PGx research. Participants included in the
PGx sub-study provided additional consent and a blood
sample for genetic research [19]. The clinical study was
conducted in accordance with the Declaration of Helsinki;
protocols and ICFs were reviewed and approved by Insti-
tutional Review Boards and Independent Ethics Commit-
tees (Additional file 1) according to local guidelines.
Genotyping and BRCA variant calling
BRCA1/2 exon genotyping was conducted in non-
accredited research laboratories using next-generation
sequencing (NGS) technologies that aimed to screen for
single nucleotide variants (SNV), and small insertions
and deletions. Reagents used were intended for research
only and were not approved for diagnostic purposes.
While terminology to describe genetic variation is emerging
[21], for simplicity the term “mutation” is used to describe
“pathogenic” or “likely-pathogenic” variants throughout this
paper. Specifically, in this work mutations in BRCA1 and
BRCA2 are defined as variants annotated as clinically
important in the Breast Cancer Information Core (BIC)
database [22]. Confidence in genotyping results was
confirmed by checking concordance with genotype data
from a genome-wide array platform (which assayed
mostly non-clinically important variants for each sam-
ple), and by manual inspection of aligned short reads
and calls when mutations were identified. BRCA1/2
genotype data were available for 664 (~71 %) of 940
clinical trial participants (hereafter referred to as pa-
tients). Ninety-seven of 664 patients (15 %) were called
as carrying a BRCA1/2 mutation [19].
Process
The pharmaceutical sponsor (GlaxoSmithKline) and the
AGO-OVAR 16 Steering Committee evaluated the
exploratory PGx results and identified the return of
BRCA1/2 results as an area for consideration. The
AGO-OVAR 16 Steering Committee was made up of
members of each collaborative research group involved
in the study, representing 17 countries (Additional file 2),
and included physicians involved in the care of patients
enrolled in the clinical trial. Clinical protocol and ICF lan-
guage relating to the handling of PGx data was reviewed
to determine likely patient understanding regarding the
return of PGx results. With genotype data generated in a
non-accredited research setting, the analytical validity of
individual research results was reviewed. In addition, the
medical importance of available BRCA1/2 data in the
AGO-OVAR 16 study population was considered. Add-
itional feedback was obtained from the sponsor’s local op-
erating companies and collaborative groups regarding
local guidelines on communication of individual genetic
research results. Ultimately the approach taken was agreed
to by members of the AGO-OVAR 16 Steering Commit-
tee and the sponsor. The sponsor confirmed that informa-
tion sent to study sites was received by the investigators
but did not determine whether investigators shared infor-
mation with their patients because the investigators were
not under any obligation to do so.
Results
Joint Sponsor and Steering Committee (JSC) considerations
The AGO-OVAR 16 PGx sub-study tested the associ-
ation between germ-line BRCA1/2 mutations and PFS in
patients receiving pazopanib versus placebo as mainten-
ance therapy [19]. While the lifetime cumulative risk of
breast or ovarian cancer is high for BRCA1/2 mutation
carriers, the actual risk conferred by a particular muta-
tion is difficult to estimate [23]. Nonetheless, BRCA1 or
BRCA2 are amongst genes identified as having direct
clinical utility [20]. Knowledge of individual BRCA1/2
mutation status may inform disease prognosis and treat-
ment decisions (e.g., continuation of platinum-based
chemotherapies, use of PARP inhibitors, increased risk
of other cancers such as breast cancer, and enrollment
into future clinical trials) and may also provide import-
ant information that the patient can share with her fam-
ily members. Consequently, consideration was given to
whether and how to return BRCA research results to pa-
tients in the AGO-OVAR 16 trial, and several options
were evaluated as described in Table 1.
These options were considered in the context of the
following: (a) medical relevance of the BRCA research
results to AGO-OVAR 16 patients, (b) information con-
tained in the study protocol and ICF, (c) ethical opinion
regarding the likely expectations of patients at the time
of enrollment, (d) the requirements for genetic counsel-
ling, and (e) the analytical validity and whether it is appro-
priate to return exploratory research data not intended for
Table 1 Options for communication of PGx data to trial
participants
Option 1: Not to proactively communicate either the individual or
aggregate research results to patients; the results will be
published in scientific journals.
Option 2: Communicate a summary of the aggregate research results
to patients, and provide them with the option to receive or
not receive their individual (research-quality) BRCA result
Option 3: Communicate a summary of the aggregate research results
and encourage patients who have not had a diagnostic-quality
BRCA test to seek pre-test counselling and a diagnostic
BRCA test.
PGx pharmacogenetic
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diagnostic purposes. Furthermore, an understanding of
the local environment and guidelines that may influ-
ence local clinical practice in a global clinical trial
were considered.
Medical relevance of BRCA test results in the AGO-OVAR
16 ovarian cancer population
While the association between BRCA germ-line muta-
tions and breast and ovarian cancer is well established,
risk estimates for the development of these cancers vary
markedly [24]. The incidence of breast cancer in BRCA
variant carriers after a diagnosis of epithelial ovarian
cancer is less than 10 % at 10 years, and overall survival
is dominated by ovarian cancer-related mortality rather
than subsequent breast cancer [25, 26]. The majority
(>91 %) of patients in AGO-OVAR 16 had late stage
(III-IV) disease [14] and, although it is difficult to pre-
dict absolute risk, our rough estimates of the proportion
of patients who would have a new primary BRCA-associ-
ated cancer occurring in this population was <5 %. Thus,
the benefit of communicating individual BRCA1/2 re-
search results with patients who already have ovarian
cancer, with respect to the risk of developing further
BRCA-related cancers, is unclear and did not overcome
the issues described below. Patients in AGO-OVAR 16
had already developed ovarian cancer and in many
cases had progressed. Nevertheless, first-degree rela-
tives of these patients may still be healthy, and know-
ledge of their BRCA status may be very informative, as
is discussed below.
Differential response to therapy by BRCA1/2 status is
another area that could be considered clinically import-
ant. Increased sensitivity to platinum-based chemother-
apy was observed in BRCA mutation carriers [17, 18],
and maintenance therapy with olaparib is most effective
in BRCA mutation carriers who had platinum-sensitive
recurrent serous ovarian cancer [16]. However, in some
countries (for example, Spain) the guidance regarding
the management of ovarian cancer does not include the
use of BRCA testing [27], but may be revised following the
approval of olaparib for the treatment of ovarian cancer in
Europe. Nonetheless, the provision of research-grade
BRCA test results may not be aligned with clinical practice
or law in some jurisdictions, presenting an ethical dilemma
that requires further consideration. Essentially, if the
research results are clinically relevant and appropriate to
return in one jurisdiction, it would be hard to argue that
they are not relevant in another jurisdiction.
While opinion supports the return of medically action-
able research results [1], clinician opinion differs on
whether patients should be directly notified of their indi-
vidual PGx research results [28]. Similarly, views varied
significantly amongst the AGO-OVAR 16 study physi-
cians regarding the appropriateness of communicating
the individual BRCA research results generated in the
study. However, there was overall general agreement that
the BRCA research results may be of interest and benefit
and that steps should be taken to find an appropriate
mechanism to share the results with study patients.
Protocol and informed consent
The AGO-OVAR 16 trial was initiated in 2009 and in-
cluded exploratory PGx research objectives. The proto-
col stated that PGx research results would not be
communicated unless they were known to be relevant to
the “participant’s medical care at the time of the study,”
because the PGx results would be preliminary and their
significance and scientific validity undetermined. The
ICF template (from which individual country ICFs were
derived) highlighted that study information not helpful
to the participant’s health-care “like most genetic re-
search” would not be returned, although new medical in-
formation found during the study would be shared with
the patients if it was considered important to their
health. The ICF template also highlighted that a partici-
pant can request medical information about themselves
once the study is completed. The ICF template further
stated that tests on patient blood samples would aim to
understand response to medicine, but would not provide
information about inherited diseases or diseases that
may develop in the future (and thus failed to anticipate
the possibility that the same genetic variants may be
associated with both response to medicine and risk of
disease). Consistent with the protocol and ICF, the PGx
sub-study evaluated the role of genetic variants, includ-
ing BRCA1/2 mutations, on response to treatments.
Local ICFs were generally consistent with the study ICF
template and collectively did not highlight that PGx
research information would be proactively returned.
Ethics opinion
The German lead ethics committee (EC) provided the
opinion that patient informed consent did not cover the
return of individual PGx research results, a view sup-
ported by the collaborative research groups involved in
the study.
Generally, research participants should have the op-
portunity to decide whether they want to receive their
individual results prior to their participation in the study
[8, 12, 29]. However, since there was no expectation that
individual PGx results would be returned, patients in
AGO-OVAR 16 were not given an opportunity to indicate
whether they wished to receive their results. An alterna-
tive approach could be to contact research participants
after completion of the PGx study to determine whether
they would like to receive individual PGx research results
retrospectively; however, this could be considered coercive
[10], that is, patients may feel compelled to receive their
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results. Indeed our discussions highlighted concerns for
patients who had previously indicated they did not want
to be contacted after completing the study. Re-contacting
these patients may cause further alarm and, although the
ethical nature of returning individual BRCA test results in
these cases can be further debated, these concerns
highlighted the difficulties of satisfying all scenarios.
Genetic counselling
The European Society of Medical Oncology (ESMO)
recommends that clinical BRCA genetic testing should
only be offered after genetic counselling [23]. The AGO-
OVAR 16 PGx analysis was planned as an exploratory
evaluation, and results were not intended for diagnosis,
prevention, or treatment of disease. Consequently gen-
etic counselling was not offered to patients at the time
of study entry. It could be argued that genetic counsel-
ling could be provided at the point patients are made
aware of the availability of their individual BRCA results.
However, France, Germany, and Scandinavian countries
(which between them recruited >40 % of the study pa-
tients in AGO-OVAR 16, and >46 % of patients with a
BRCA mutation were from these countries) indicated
that genetic counselling qualifications would be required
for investigators to discuss genetic results with their
patients, but that not all study investigators had the ne-
cessary qualification. There is a recognized shortage of
genetic counselors; for instance, there is approximately 1
genetic counselor to every 80,000 people in the United
States [30]. Thus, while investigators had resources to
contact patients to share results as part of the clinical
study, the availability and variability in genetic counsel-
ling requirements presented a significant limitation for
patients to discuss their research results and seek guid-
ance on follow-up. Ambiguity in the interpretation of in-
dividual BRCA test results has been reported [31, 32],
further emphasizing the need for qualified genetic coun-
selors in communicating genetic research findings such
as those described in this study. Alternative genetic
counselling models, such as telephone counselling and
telegenetics, have been proposed in the oncology setting
and may be a suitable approach where resources are lim-
ited. However, these approaches still require comparative
effectiveness studies to fully evaluate short- and long-
term patient outcomes [33] and as such may not have
been suitable in this study. Clearly anticipating the need
for genetic counselling is a key learning from this study,
and in the future, sponsors of clinical trials should care-
fully consider resource needs and at what stage of the
trial they should be incorporated.
Analytical validity of BRCA research results in AGO-OVAR 16
When offering individual test results to research partici-
pants, procedures should be in place to ensure that the
analyzed sample is actually from the person it is believed
to be from [34] and the results should be independently
confirmed for accuracy [11]. Indeed, the 2010 Genetic
Diagnostic Act of Germany requires that research partic-
ipants who wish to receive their genetic results must be
re-tested at an approved genetic laboratory [35]. Further-
more, in Germany having a research-quality BRCA test
result would not necessarily qualify a patient for a con-
firmatory diagnostic test because referral is only available
in cases of platinum-sensitive ovarian cancer relapse or
where the patient fulfills the eligibility criteria for the
consortium of hereditary breast or ovarian cancer. With
ever-increasing access to genetic testing through partici-
pation in research and the likelihood of incidental find-
ings, it will become necessary to update eligibility
criteria where participants obtain research-quality BRCA
test results. Ensuring that BRCA test results are included
in eligibility criteria for diagnostic testing may inform a
potential preventative approach where disease has not
yet developed. In the United States, the Center for Medi-
care and Medicaid Services (CMS) currently interprets
CLIA (Clinical Laboratory Improvement Amendments)
regulations as prohibiting the return of non-accredited
results for treatment or health-assessment purposes.
Furthermore, the return of these results to enable re-
search participants to seek counselling or a confirmatory
test in a CLIA-certified laboratory is considered as
“treatment” by the CMS. In contrast, for entities covered
by the Health Insurance Portability and Accountability
Act of 1996 (HIPAA), the recently amended HIPAA
“Privacy Rule” provides research participants with broad
rights to access their individual results held in desig-
nated records irrespective of the environment in which
the results were generated, a position that appears to be
inconsistent with CLIA-regulation [36]. Thus, with re-
gard to research results that have potential clinical rele-
vance, researchers may be faced with contradiction in
law and may be reluctant to return results due to the
risks that study participants may misinterpret or misuse
them. Such inconsistency clearly requires clarification at
both national and international levels as researchers are
currently faced with the possibility of violating regula-
tions for whichever approach is taken. Indeed, the US
HHS Secretary’s Advisory Committee on Human Re-
search Protections (SACHRP) recently highlighted this
inconsistency and recommended urgent clarification to
resolve the regulatory conflicts [37], recommendations
that still require implementation. Unfortunately at an
international level, attempts to harmonize policy and
guidelines are overdue and researchers continue to be
faced with regional differences.
In the AGO-OVAR 16 study PGx blood samples were
collected for exploratory PGx research. PGx blood sam-
ples were tracked from the point of collection through
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DNA extraction and genotyping. Although there was a
high degree of confidence that a sample for any given in-
dividual was indeed from that individual, the tracking
system was not externally validated (but was appropriate
for exploratory analyses). BRCA genotyping was con-
ducted in non-accredited research laboratories using
NGS technologies and reagents designated for research
use only. Comparisons with independent array-based
genotyping of exonic BRCA1/2 variants confirmed high
accuracy for the NGS approach. Individual genotype
data were compared to the BIC database to identify clin-
ically important BRCA mutations. While a positive
match indicated a high chance that the variant carried
by an individual is clinically important, there was a po-
tential for false-negative calls because it is unlikely that
the BIC database included all (likely) pathogenic BRCA
mutations. While samples were still available, they were
stored long term in a central repository where sample
tracking was not validated for diagnostic purposes; thus,
there would be a residual issue of analytical validity if
these samples were re-tested in an accredited environ-
ment. Essentially, the methods employed were not ap-
proved for individual diagnostic purposes but were aligned
for population PGx research that sought to understand the
relationship between BRCA mutation status and response
to treatments.
Returning aggregate BRCA research results
Overall, our evaluation recognized the importance of
communicating BRCA research results to patients; how-
ever, many issues (e.g., ICF, local regulation, and guid-
ance) exist that would challenge the appropriateness of
proactively communicating individual BRCA1/2 research
results to patients in AGO-OVAR 16. Therefore, we
considered an alternative approach, advocated by some
commentators [38], to proactively communicate the ag-
gregate genetic result to patients via investigators. Pa-
tients could then request their individual results if they
desired. While aggregate PGx results are frequently re-
ported in peer-reviewed publications, they are rarely
provided directly to individual study participants [5, 38].
Although challenges do exist with the communication of
aggregate genetic results [5], they are not insurmount-
able. We developed an approach to return the aggregate
BRCA1/2 result to patients via study investigators
(Fig. 1). Briefly, the pharmaceutical sponsor provided a
“Dear Investigator Letter” (Additional file 3) that sum-
marized the key findings of the PGx research. Based on
feedback from local investigators and operating compan-
ies, a number of circumstances were identified where it
may be inappropriate to contact patients or where local
laws restricted the return of research results. Thus, in-
vestigators were not mandated to share the aggregate
BRCA1/2 study findings, and a mechanism for tracking
what the investigators did was therefore not established.
Study investigators were encouraged to contact surviving
study patients to inform them of the overall BRCA1/2
findings in relation to PFS, and, based on local guide-
lines, test availability and individual circumstances, to
discuss whether it would be appropriate to seek genetic
counselling and a diagnostic quality BRCA1/2 test. Study
patients would benefit from understanding the research,
why it was conducted, the implications to them and
their family, and would be in a better position to make a
more informed decision regarding follow-up. Contact
with family members of deceased trial participants was
not recommended because it was outside the scope of
the informed consent and thus, by law, not allowed in
some countries or allowed only in exceptional circum-
stances in other countries [39]. Additional circumstances
under which it may be inappropriate to contact partici-
pants included patient withdrawal of consent, previous
BRCA testing by a diagnostic laboratory, or progressive
disease such that BRCA status would not change or
affect decision on further treatment options. Investiga-
tors were asked to determine local requirements and
seek necessary approvals prior to making contact with
surviving study participants.
Discussion
Technological advances provide an opportunity to gain
greater understanding of the relationship between genetic
variation, disease, and response to medicines. However,
the increasingly routine approaches of whole-exome or
Fig. 1 Process for the return of aggregate BRCA research results to patients enrolled in AGO-OVAR 16. PGx, pharmacogenetic
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whole-genome sequencing using NGS, where the analysis
aims to identify rare variants associated with drug re-
sponse, heightens the probability of incidental findings
and the discovery of variants of unknown significance
[31]. This potentially increases the burden on local in-
vestigators and counselling and testing facilities and
raises questions of how researchers should manage gen-
etic results. The ongoing ethical debate regarding the
benefits, risks and utility of returning individual genetic
research-quality results has generally failed to consider
the complexities of working in an international clinical
trial setting, where variations exist in regulation, guid-
ance, and ethical opinion. Guidance for the communi-
cation of results exists, but there is a lack of agreement
and a need for harmonization across countries [9].
At the time the AGO-OVAR 16 study was set up, gen-
eral practice was not to communicate individual explora-
tory PGx results. This approach was aligned with ethical
guidance in many countries on the handling of explora-
tory genetic data [5] and with EC opinion, which often
required consent forms to stipulate that individual ex-
ploratory genetic results would not be returned [10]. In
AGO-OVAR 16, scientists, investigators, and representa-
tive physicians involved in the care of patients were dir-
ectly involved in the decision process, and a wide variety
of diverse perspectives were represented. These opinions
varied from those advocating the complete proactive
communication of individual BRCA research results to
all patients to those advocating no proactive communi-
cation at all. Very real challenges were encountered in
reaching a consensus opinion that addressed all view-
points yet was consistent with constraints from the his-
toric trial design. While the communication of individual
BRCA1/2 data may provide benefit for some study pa-
tients, and was considered, the fact that the initial con-
senting process did not involve a discussion about the
return of research-quality PGx results was viewed as a
significant barrier to communicating individual results.
Furthermore, a clinical decision to conduct diagnostic
testing for BRCA mutation status would be influenced by
specific local eligibility criteria at the time of diagnosis. Pa-
tients at highest risk of carrying a mutation in BRCA1/2
(e.g., those with a family history and/or early age of disease
onset) are more likely to meet the eligibility criteria for a
diagnostic test, and thus many patients identified in this
study as BRCA-positive may already be aware of their
BRCA status. It is therefore not clear that access to a re-
search test result several years after initial diagnosis would
alter this initial decision or meet eligibility criteria for
diagnostic testing in some countries. Our assessment
highlighted that while there may be good cause to return
individual BRCA research test results, particularly for
patients called as BRCA-positive, we were nonetheless
constrained by local requirements restricting the return of
research results. Importantly, the informed consent
document presented patients an opportunity to request
individual results generated during the study. Thus any
patient would be able to request their individual BRCA
research test result after receiving the aggregated result.
It could be argued that our approach to proactively
communicate the aggregate research result rather than
proactively communicate individual results to study
participants may not be optimal with regard to re-
searcher’s ethical duty to patients as it relies on patients
taking the initiative to request their own data. However,
in our view, the pragmatic approach taken here pro-
vided patients with the opportunity to request their in-
dividual data, thus fulfilling the obligation of autonomy
and complying with local restrictions and the ICF.
An acknowledged limitation of our approach is that
patient advocacy groups were not involved in the deci-
sion process. In hindsight, such input could have pro-
vided valuable insights to inform our understanding of
international variability in patients’ attitudes towards the
return of individual genetic research results and may
have served to heighten debate on this difficult topic.
It is, however, unclear how this would have modified
the ultimate decision taken for AGO-OVAR 16 given
the constraints identified. We hope that the issues
highlighted in this paper will help to stimulate discus-
sions involving cross-disciplinary parties, including
patient advocacy groups.
The return of aggregate results provides a mechanism
to convey research findings to patients, which demon-
strates reciprocity where the sharing of individual results
is not appropriate [38] and fulfills ethical obligations
found in the Helsinki declaration [9]. Although it is not
yet clear whether exploratory PGx research results are in
scope, Clinical Trial Regulation (CTR) EU No. 536/2014
[40] will require sponsors to provide a lay summary of
aggregate clinical trial results for submissions in Europe,
further emphasizing an increased desire for greater
transparency. Study investigators have the benefit of a
direct relationship with the patient, thereby understand-
ing their individual circumstances (e.g., whether they
have previous diagnostic-quality BRCA1/2 test result),
and are best suited to describe the aggregate findings in
appropriate lay terms and to highlight key distinctions
between research and healthcare settings, thus helping
to avoid potential therapeutic misconception that could
result in harm, including emotional distress. Further-
more, they have an understanding of clinical practice in
terms of local counselling and confirmatory testing
options. Feedback from one country highlighted that
investigators communicated the aggregate results to all
patients together with the recommendation to seek fur-
ther explanation from a genetic counselor. More than
50 % of patients in this country did seek follow-up but
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encountered limited availability of local genetic counsel-
ling and testing facilities. This experience highlights
some of the constraints that investigators and patients
may encounter when seeking specialist resources and
emphasizes the need to consider these challenges during
the design of new clinical trials, particularly in an inter-
national setting where access to resources may vary
between countries.
The sharing of aggregate results may trigger a desire
from participants to know their individual BRCA result
if they do not already have a diagnostic-quality test re-
sult. Thus, by sharing aggregate results it will be neces-
sary to prepare for requests for individual BRCA results.
Requests would be handled through the patient’s study
investigator, and individual BRCA results would carry
the caveat that they were not intended for the diagnosis,
prevention, or treatment of disease.
Study participants who request and obtain their
BRCA1/2 research results (or who have a diagnostic
quality BRCA1/2 test result) may choose to subsequently
share the information with relatives. The potential for
relatives to make an informed decision to seek their own
diagnostic quality BRCA1/2 test and subsequent follow-
up (e.g., seek risk-reducing surgery) may arguably be
considered a significant benefit of returning BRCA1/2
information to patients who already have ovarian cancer.
However, the relationship between clinical study patients
and researchers often does not extend to family mem-
bers, and interaction between researchers and family
members was outside the scope of the AGO-OVAR 16
consent. Furthermore, the sharing of research results
directly with relatives (e.g., where the patient is de-
ceased) would be contrary to law in many countries
were legislation exists [39]. Although the approach taken
here may be considered controversial, there is nonethe-
less a clear challenge for researchers who are faced with
the dilemma of conflicting ethical and legal frameworks.
The occurrence of unexpected incidental findings is
hardly new and is likely to recur in future studies. We
would argue that current law and guidelines should be
revised to provide researchers with a clear picture of
how to proceed where there is a strong ethical argument
to share results with patients or their relatives but where
the sharing of such data was unanticipated.
Although resources to communicate the aggregate re-
sult to patients were in place, these did not extend to
genetic counselling or confirmatory diagnostic-quality
testing, which was outside the scope of the study proto-
col. Future clinical trial protocols should describe clearly
the possibility that genetic research data may be com-
municated under some circumstances and describe the
mechanism of dissemination. The ICF should provide
research participants with the opportunity to “opt-in” or
“opt-out” with respect to the communication of
individual genetic research results. This approach would
need to take into account different requirements and re-
sources for genetic counselling and confirmatory testing
between jurisdictions and consider what action to take
where a participant initially opted to receive medically
important research findings, but later withdrew from the
study or became lost to follow-up. Our experience dem-
onstrates that a single approach for all participants
enrolled in international studies may be difficult to
achieve, and that it may be necessary for local solutions
to be developed based on locally available resources,
requirements, and ethical guidance.
Ideally individual genetic results should be returned
when the clinical trial produces clinically useful data for
a validated biomarker [11] and when the research result
is analytically valid [41]. However for clinical trials,
changes to current processes would be required to en-
sure study participants understand the circumstances
under which their genetic research results would be
returned. In future clinical trials, during study enrol-
ment, sponsors would specify that medically important
genetic research results will be returned to participants
who wish to receive them. Study sponsors could then
take one of a number of approaches (A, B, and C) as
summarized in Table 2.
While approach (A) may be desirable, the burden on
sponsors, clinical site staff, and study participants to re-
connect, re-sample, and re-test in an accredited environ-
ment, perhaps many years after participants ended their
involvement in the study, presents practical and resource
challenges. Approach (B) may negate the need to recon-
nect with study participants but would increase study
costs and resources. Because the primary purpose of
genetic research is not diagnostic in nature, recommen-
dations requiring all clinical trials to be set up to enable
the independent validation of individual genetic data or
to conduct research in an accredited environment (when
in the vast majority of cases the research is exploratory),
are unlikely to be adopted voluntarily. Alternatives to
collecting and storing participant samples in an accre-
dited environment and taking an aliquot for exploratory
Table 2 Approaches to disseminate medically important genetic
research results
Option A: In the event of a medically important finding when
conducting exploratory genetic research, contact participants
and seek consent to collect a second sample for the purpose
of a diagnostic confirmatory test.
Option B: Conduct all aspects of genetic research in an accredited
environment.
Option C: Communicate medically relevant genetic research results to
study participants who opt to receive their individual genetic
research results, via clinical investigator and after appropriate
genetic counselling. Advise study participants that they would
need to seek a diagnostic confirmatory test.
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genetic research could be considered, but again such al-
ternatives would incur additional study costs when for
the majority of cases, a confirmatory test would not be
required. Where a clinical trial incorporates a predefined
genetic research objective that involves testing of genetic
markers with an established clinical utility, there is a
strong argument that the genetic research should be
conducted in an accredited environment that meets
recognized criteria for analytical validity.
As long as it is clear to study participants who opt to
receive their individual genetic research results that the
responsibility for seeking a confirmatory diagnostic test
does not reside with researchers, we would advocate ap-
proach (C). The responsibility for interpreting individual
results would reside with the participant in consultation
with qualified specialists who can evaluate the genetic
research results and future risk for conditions that are
likely multi-factorial. Furthermore, this approach will
enable study participants to seek the follow-up most
appropriate to their personal circumstances and local
environment. While fulfilling a responsibility of re-
searchers and physicians to share clinically relevant re-
search results, this approach would minimize the need
to maintain study resources, potentially for many years
after conclusion of the clinical study, and is likely to be
more desirable for sponsors and clinical site investiga-
tors. This approach also offers the opportunity for inves-
tigators to track and maintain contact with research
participants who opt to be informed of incidental find-
ings that may affect their health or that of their relatives.
Indeed, if the informed consent process had provided
patients with the option to be re-contacted to provide
their provisional BRCA research test result, a different
approach may have been possible in AGO-OVAR 16. It
may have presented an opportunity to share individual
results specifically for those patients called as carrying a
medically important BRCA mutation and who opted to
be contacted in these circumstances. Irrespective of the
approach taken, sponsors would need to remain cognizant
of regulations and guidance that restrict return of research
results (e.g., CLIA-regulation in the US) and that differ-
ences in requirements may exist between countries. It will
be necessary to tailor the approach based on local law,
regulation, and EC advice.
Conclusion
Our experiences highlight the need for careful consider-
ation and awareness of local law, clinical practice, and
ethics guidance, all of which may differ between countries.
In international clinical trial settings, a single approach
may not be appropriate when considering communication
of individual genetic research results. At the time the
AGO-OVAR 16 protocol was developed, the ethical, regu-
latory, and professional consensus was to not return
genetic research results to study participants. This pos-
ition has subsequently evolved and will continue to do so
in the future. Using our experience from AGO-OVAR 16,
a process was developed for the return of aggregate PGx
research results to clinical trial participants that can be
used in future clinical trials. While the approach taken in
this study is not without its limitations, and opinions on
the merits of the approach will vary, it was considered
a reasonable approach given the lack of consensus of
opinion. This study does highlight the need for further
debate and the need to resolve current legal inconsist-
encies at national and international levels. Our experi-
ence highlights that post-hoc decisions regarding the
communication of genetic research results are seldom
satisfactory. Given the rapid pace of change in genetic
research it is likely scenarios will continue to arise that
were unanticipated at study design. A recent proposal
to establish a secondary-genomic-findings service to
support researchers in the return of individual clinically
actionable genetic research findings may provide one
solution in these cases [2]. Our study illustrates the im-
portance of increasing the clarity and scope of informed
consent to ensure clinical trial participants can indicate
their preference regarding receipt of potentially import-
ant individual genetic results and to account for un-
anticipated “incidental findings.” Future clinical trials
should proactively consider the strategy for communi-
cating genetic research data to patients and the envir-
onment (accredited or non-accredited) in which genetic
research is to be conducted.
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